Author

Andrew Hillman

Observed names: Hillman, Andrew, Hillman, Andrew Jonathan

ORCID: 0009-0001-5396-321X

Observed ORCID: 0009-0001-5396-321X

OpenAlex ID: A5139488776

Mesenchymal Stem Cell-Derived Exosomes from Wharton's Jelly: The Gold Standard for Safe, Compliant Regenerative Medicine

2026 · Hillman, Andrew · Zenodo (CERN European Organization for Nuclear Research) · 1

Wharton's Jelly Mesenchymal Stem Cell-Derived Exosomes as an Adjunctive and Alternative Therapeutic Strategy in Spinal Disc Repair, Post-Surgical Recovery, and as a Replacement for FDA-Unindicated Epidural Corticosteroid Injections

2026 · Jenani, Keyon, Hillman, Ashton, et al. · Zenodo (CERN European Organization for Nuclear Research) · 1

The Shred Bin Is Evidence

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

How to Write a Healthcare Compliance Expert Report That Survives Rule 702

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

Pathway Diligence Before the Check Clears

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

The R3 Medical Warning Letter Is a Pattern, Not a Mood

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

After the Tissue Grey Market Warning Letters, What Clinics Should Pressure-Test Before a CID Arrives

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

What Retaining Counsel Actually Needs from an Operator Expert

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

The Permission Gap

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

Sponsor kills ExoFlo perianal fistula trial after enrolling five patients

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

The False Claims Act Is the Biggest Compliance Risk in Healthcare. Most Programs Are Not Built for It.

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

Paradigm Peptides Was the Warm-Up. The Tissue Grey Market Is the Real Target.

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

The CMC chasm. Why most biotech IND submissions fail at chemistry, not biology.

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

What "non-toxic cancer treatment" actually means

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

Mesenchymal Stromal Cell-Derived Exosomes and Extracellular Vesicles Across Therapeutic Indications A Structured Review of Published Preclinical and Early-Phase Clinical Study Designs, Administration Parameters, and Reported Outcomes

2026 · Hillman, Andrew · Zenodo (CERN European Organization for Nuclear Research)

Mesenchymal Stem Cell-Derived Exosomes from Wharton's Jelly Umbilical Cord: Regulatory Superiority Under FDA CBER Section 351(a) and the Federal and State Legal Violations of Non-Compliant Section 361 HCT/P Grey Market Products

2026 · Hillman, Andrew · Zenodo (CERN European Organization for Nuclear Research)

From our Research, The Biologics Paradigm: Wharton's Jelly Mesenchymal Exosomes as a Section 351(a) Drug vs. The Section 361 Regulatory Grey Market

2026 · Hillman, Andrew · Zenodo (CERN European Organization for Nuclear Research)

When RMAT designation actually helps you. And when it is a marketing pin.

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

Voltage-gated sodium channels in cancer. The biology, explained for non-scientists.

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

Your stage-4 second opinion checklist (no fluff)

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

The Pre-IND Meeting. What CBER Reviewers Actually Want to See.

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

The NextMed Settlement Is a Roadmap. Read It Before You Build the Next Telehealth Brand.

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

RMAT or BLA. When to chase Regenerative Medicine Advanced Therapy designation, and when to wait.

2026 · Hillman, Andrew Jonathan · Zenodo (CERN European Organization for Nuclear Research)

Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tissue Repair Across Multiple Body Systems: A Narrative Review

2026 · Hillman, Andrew Jonathan, Jenani, Keyon · Zenodo (CERN European Organization for Nuclear Research)

Works count: 24

Citation count: 2

H-index: 1

I10-index: